Online citations, reference lists, and bibliographies.

Establishment Of A Tumor Sphere Cell Line From A Metastatic Brain Neuroendocrine Tumor

Ryoichi Iwata, M. Maruyama, T. Ito, Y. Nakano, Y. Kanemura, Taro Koike, Souichi Oe, K. Yoshimura, M. Nonaka, S. Nomura, T. Sugimoto, H. Yamada, A. Asai
Published 2017 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Neuroendocrine tumors are rare, and little is known about the existence of cancer stem cells in this disease. Identification of the tumorigenic population will contribute to the development of effective therapies targeting neuroendocrine tumors. Surgically resected brain metastases from a primary neuroendocrine tumor of unknown origin were dissociated and cultured in serum-free neurosphere medium. Stem cell properties, including self-renewal, differentiation potential, and stem cell marker expression, were examined. Tumor formation was evaluated using intracranial xenograft models. The effect of temozolomide was measured in vitro by cell viability assays. We established the neuroendocrine tumor sphere cell line ANI-27S, which displayed stable exponential growth, virtually unlimited expansion in vitro, and expression of stem-cell markers such as CD133, nestin, Sox2, and aldehyde dehydrogenase. FBS-induced differentiation decreased Sox2 and nestin expression. On the basis of real-time PCR, ANI-27S cells expressed the neuroendocrine markers synaptophysin and chromogranin A. Intracranial xenotransplanted brain tumors recapitulated the original patient tumor and temozolomide exhibited cytotoxic effects on tumor sphere cells. For the first time, we demonstrated the presence of a sphere-forming, stem cell-like population in brain metastases from a primary neuroendocrine tumor. We also demonstrated the potential therapeutic effects of temozolomide for this disease.
This paper references
10.1038/nmeth758
Neural stem cells and neurospheres—re-evaluating the relationship
B. Reynolds (2005)
10.1038/bmt.2012.244
Investigation of the freely available easy-to-use software ‘EZR' for medical statistics
Yasunari Kanda (2013)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C. Yao (2008)
10.1002/cncr.29099
Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Julie Hallet (2015)
10.1016/S1470-2045(07)70410-2
Gastroenteropancreatic neuroendocrine tumours.
Irvin Mark Modlin (2008)
10.1126/science.1553558
Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.
B. Reynolds (1992)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
10.1038/nn.3510
Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake
William A Flavahan (2013)
10.1073/pnas.1600007113
Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors
G. Krampitz (2016)
O 6methylguanine DNA methyltransferase deficiency and response to temozolomidebased therapy in patients with neuroendocrine tumors
ME Hegi (2009)
10.1186/s12967-016-0857-1
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Chiara De Divitiis (2016)
10.1200/JCO.2011.40.3147
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Jennifer A. Chan (2012)
10.1186/s40001-014-0066-4
Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome
Yu Bai (2014)
10.1200/JCO.2007.11.5964
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
M. Hegi (2008)
10.1097/01.pai.0000210416.53493.0f
Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin
Xiaoqi Lin (2007)
Serine/threonine kinase MLK4 determines mesenchymal identity in glioma stem cells in an NF-kappa B-dependent manner. Cancer Cell 29:201–213
SH Kim (2016)
10.1200/JCO.2014.60.2532
Carcinoid and neuroendocrine tumors: building on success.
Pamela L. Kunz (2015)
10.1038/sj.cdd.4402283
Identification and expansion of the tumorigenic lung cancer stem cell population
Adriana Eramo (2008)
10.4161/cc.10.9.15486
Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform
Paola Marcato (2011)
10.1159/000333035
The Novel WHO 2010 Classification for Gastrointestinal Neuroendocrine Tumours Correlates Well with the Metastatic Potential of Rectal Neuroendocrine Tumours
Juha Jernman (2012)
10.1016/j.clineuro.2014.08.004
11C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas
Yoshiko Okita (2014)
10.1016/j.ccell.2016.01.005
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.
Sung-Hak Kim (2016)
10.1158/1078-0432.CCR-08-1476
O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke (2009)
10.1002/cncr.24406
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Alba A Brandes (2009)
10.1002/cncr.11105
A 5-decade analysis of 13,715 carcinoid tumors.
Irvin Mark Modlin (2003)
Serine / threonine kinase MLK 4 determines mesenchymal identity in glioma stem cells in an NFkappa Bdependent manner
T Lapidot (2016)
10.1038/367645a0
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
T. Lapidot (1994)
10.1158/1078-0432.CCR-06-2053
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Sara Ekeblad (2007)
10.1053/j.gastro.2011.07.037
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.
Puja Gaur (2011)
10.1038/sj.bjc.6690325
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Emmanuel Mitry (1999)
10.1200/JCO.2005.03.6046
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Matthew H. Kulke (2006)
10.1139/bcb-2012-0100
Research on DNA methylation of human osteosarcoma cell MGMT and its relationship with cell resistance to alkylating agents.
Jun Guo (2013)
10.3892/ijo.2012.1592
Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties.
Xin Hong (2012)
O 6 -Methylguanine DNAMethyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke (2009)
10.1089/scd.2008.0055
ALDH1 as a functional marker of cancer stem and progenitor cells.
Julie Douville (2009)
10.1016/j.stem.2007.08.014
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
C. Ginestier (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar